Charles River Laboratories Invests US$500 Million in Cambodia’s Biomedical Research
Dieser Artikel ist in dieser Sprache noch nicht verfügbar. Sie lesen das englische Original.
U.S. biotechnology company Charles River Laboratories has announced a US$500 million investment in Cambodia aimed at strengthening biomedical research and scientific infrastructure. The project will establish a biomedical research and regulated breeding facility to support health-related studies and scientific research in the country.
Cambodian government officials highlighted the project’s strategic significance for the nation’s economic and scientific development. The facility will operate under strict international standards, including ethical protocols for animal welfare and global scientific regulations. The government confirmed that all operations will comply with established frameworks to ensure transparency and responsible practices.
The investment is expected to create numerous high-skilled technical jobs, diversify economic opportunities beyond Cambodia’s traditional sectors, and enhance the country’s scientific capabilities. Authorities noted that the project will also contribute to improved biosecurity and animal health standards, while fostering technology transfer and workforce development for local communities.
In addition to infrastructure and research support, Charles River Laboratories has committed to an annual fund focused on community development, including initiatives in education, healthcare, and clean water access within the region. This highlights the company’s effort to integrate corporate social responsibility alongside its investment in life sciences.
The US$500 million project reflects growing confidence from international investors in Cambodia’s evolving business environment. Analysts see it as part of a broader trend of foreign investment in sectors that support scientific research, innovation, and life sciences development. By establishing advanced research facilities, Cambodia positions itself as an emerging hub for global biomedical partnerships, attracting further international collaboration and expertise.
This significant investment by Charles River Laboratories underscores the potential for sustainable economic growth through high-value, knowledge-based sectors, strengthening Cambodia’s role in the global biotechnology and life sciences ecosystem.
Also Read: Shijiazhuang Hongray Group Seeks Cambodia Site for Medical Plant
